GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generex Biotechnology Corp (OTCPK:GNBTQ) » Definitions » Operating Income

Generex Biotechnology (Generex Biotechnology) Operating Income : $-34.12 Mil (TTM As of Apr. 2021)


View and export this data going back to 1998. Start your Free Trial

What is Generex Biotechnology Operating Income?

Generex Biotechnology's Operating Income for the three months ended in Apr. 2021 was $-6.36 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Apr. 2021 was $-34.12 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Generex Biotechnology's Operating Income for the three months ended in Apr. 2021 was $-6.36 Mil. Generex Biotechnology's Revenue for the three months ended in Apr. 2021 was $0.02 Mil. Therefore, Generex Biotechnology's Operating Margin % for the quarter that ended in Apr. 2021 was -30,300.00%.

Generex Biotechnology's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Generex Biotechnology's annualized ROC % for the quarter that ended in Apr. 2021 was -42.78%. Generex Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2021 was 12,779.90%.


Generex Biotechnology Operating Income Historical Data

The historical data trend for Generex Biotechnology's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generex Biotechnology Operating Income Chart

Generex Biotechnology Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.90 -1.60 -2.50 -21.09 -17.74

Generex Biotechnology Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.57 -5.07 -14.11 -8.58 -6.36

Generex Biotechnology Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Apr. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Generex Biotechnology  (OTCPK:GNBTQ) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Generex Biotechnology's annualized ROC % for the quarter that ended in Apr. 2021 is calculated as:

ROC % (Q: Apr. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2021 ) + Invested Capital (Q: Apr. 2021 ))/ count )
=-25.452 * ( 1 - 0% )/( (58.389 + 60.59)/ 2 )
=-25.452/59.4895
=-42.78 %

where

Note: The Operating Income data used here is four times the quarterly (Apr. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Generex Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2021 is calculated as:

ROC (Joel Greenblatt) %(Q: Apr. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2021  Q: Apr. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=38.148/( ( (0.324 + max(-48.358, 0)) + (0.273 + max(-54.646, 0)) )/ 2 )
=38.148/( ( 0.324 + 0.273 )/ 2 )
=38.148/0.2985
=12,779.90 %

where Working Capital is:

Working Capital(Q: Jan. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.169 + 0.618 + 0.39) - (45.033 + 4.502 + 0)
=-48.358

Working Capital(Q: Apr. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.052 + 0.232 + 0.51) - (46.938 + 8.502 + 0)
=-54.646

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Apr. 2021) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Generex Biotechnology's Operating Margin % for the quarter that ended in Apr. 2021 is calculated as:

Operating Margin %=Operating Income (Q: Apr. 2021 )/Revenue (Q: Apr. 2021 )
=-6.363/0.021
=-30,300.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Generex Biotechnology Operating Income Related Terms

Thank you for viewing the detailed overview of Generex Biotechnology's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Generex Biotechnology (Generex Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
10102 USA Today Way, Miramar, FL, USA, 33025
Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.
Executives
Prioletti Mark Joseph Se director 1121 PALMER COURT CRYSTAL LAKE IL 60014
Salvo Lawrence Anthony Sr director 450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139
Harold Gray Haines other: Consultant 11511 SW 127TH ST MIAMI FL 33176
Mark Fletcher officer: EVP General Counsel &Secretary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Brian Mcgee director 201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000
Anderson James H Jr. director 33 HARBOUR SQUARE TORONTO A6 M5J2G2
Mark Corrao officer: CFO & Treasurer 531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825
Purcell Richard David Jr. director, officer: SVP of Research & Drug Develop 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
Gary Herbert Lyman director 10102 USA TODAY WAY MIRAMAR FL 33025
Kevin Centofanti director 10102 USA TODAY WAY MIRAMAR FL 33025
Andrew Ro director, officer: SVP & Chief Investment Officer 10102 USA TODAY WAY MIRAMAR FL 33025
David Brusegard officer: Chief Operating Officer 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Stephen Fellows officer: Chief Financial Officer 33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2
Hofe Eric Von director, officer: President of Subsidiary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
John P Barratt director 555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1

Generex Biotechnology (Generex Biotechnology) Headlines

From GuruFocus